GA
JUNO

Geneva Advisors’s Juno Therapeutics, Inc. JUNO Stock Holding History

Geneva Advisors’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-5,975
Closed -$312K – 746
2014
Q4 		$312K Buy
+5,975
New +$267K 0.01% 503

Other funds holding JUNO

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Geneva Advisors's JUNO Position: Q1 2015 in Review

Geneva Advisors sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2015, closing a stake of 5,975 shares — an estimated $312K sold.

Geneva Advisors first reported a position in JUNO in Q4 2014 and held it in 1 quarter. The position peaked at $312K in Q4 2014. 120 funds tracked by Wall St. Rank hold JUNO as of Q1 2015.

  • Geneva Advisors reported no remaining Juno Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
  • Geneva Advisors sold 5,975 Juno Therapeutics, Inc. shares in Q1 2015, an estimated $312K.
  • Geneva Advisors first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 1 quarter.
  • Geneva Advisors's Juno Therapeutics, Inc. position peaked at $312K in Q4 2014.
  • 120 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2015.

Based on Geneva Advisors's 13F filing for Q1 2015, filed 5 May 2015.